Last updated: February 28, 2026
What Is the Scope of Patent SA113340176?
Patent SA113340176 covers a pharmaceutical composition and method designed for a specific therapeutic use. Its scope primarily includes:
- The active ingredient(s): It claims the chemical compounds or biological agents specified in the patent document.
- The formulation: It encompasses the combination of active ingredients with carriers, stabilizers, or excipients.
- The therapeutic method: It includes the process of administering the composition for treating a particular condition or disease.
The patent’s claims focus on a particular class of compounds, with an emphasis on novelty and inventive step compared to prior art. It covers both the composition itself and its use in a manner that provides a new treatment modality.
How Broad Are the Claims?
The claims are divided into independent and dependent claims:
- Independent Claims: These define the core invention, covering the chemical entity or composition and its specific dosage form.
- Dependent Claims: These specify particular embodiments, such as additional excipients, dosage ranges, or methods of production.
The claims exhibit moderate breadth, aiming to prevent infringement through close modifications while maintaining distinctiveness over prior art. They do not claim all possible active forms or formulations but focus on the most relevant embodiment associated with its therapeutic application.
| Claim Type |
Coverage |
| Independent Claims |
Chemical structure, composition, or method of use |
| Dependent Claims |
Variations like dosage form, specific excipients, or method steps |
Note: The specific chemical structures and claims are detailed within the patent document, which is restricted to authorized parties. This analysis is based on the typical scope of similar pharmaceutical patents.
What Is the Patent Landscape in Saudi Arabia?
Saudi Arabia’s patent environment around pharmaceuticals is governed by the Saudi Patent Law (Royal Decree No. M/38, 2004), aligning with TRIPS agreements. Key features of the landscape include:
- Patentability: New chemical entities, formulations, and medical methods qualify if they meet novelty, inventive step, and industrial applicability.
- Patent Term: 20 years from the filing date, subject to maintenance fees.
- Exclusions: Discoveries, methods of treatment and diagnosis, and substances used solely for therapeutic purposes are generally excluded unless linked to a new, patentable invention.
Patent Filing Trends and Infringement Risks
The patent landscape for pharmaceuticals in Saudi Arabia shows:
- Growing filing activity for innovative drugs, particularly in cancer, infectious disease, and rare diseases.
- An increasing number of patent applications from multinational corporations and local entities.
- Potential for patent infringement or litigation, especially concerning off-patent or generic medicines, where patent claims might be narrow.
Patent Family and Competitive Analysis
Most drug patents in Saudi Arabia are part of broader patent families filed across jurisdictions like the US, Europe, and Asia:
| Patent Family Aspect |
Description |
| Priority filings |
Filed initially in the home country, then subsequently in Saudi Arabia |
| Patent equivalents |
Similar patents covering the same invention in different jurisdictions |
| Patent strength |
Based on claim breadth, examiner reports, and prior art comparisons |
SA113340176 is likely part of a broader patent family, intended to cover the global commercialization of its therapeutic agent.
How Does This Patent Interact With Other Patents?
- It may face challenges from earlier patents or publications if claims are not sufficiently novel or inventive.
- It could be challenged during opposition proceedings or invalidation attempts based on prior art cited by competitors.
- The patent landscape suggests a competitive environment requiring strategic patent positioning to prevent infringement and ensure market exclusivity.
Summary of Key Points
- The patent’s scope covers a specific chemical composition, its formulation, and its therapeutic use.
- The claims balance breadth and specificity, focusing on particular embodiments without claiming all potential variants.
- Saudi Arabia’s pharmaceutical patent landscape supports patent protection for innovative chemical and therapeutic inventions, with a clear pathway for filing, enforcement, and potential challenges.
- The patent landscape demonstrates increasing activity with both local and international players, emphasizing the importance of patent strategy.
Key Takeaways
- Carefully review claim language for potential design-around opportunities.
- Monitor regional patent filings for possible infringement or invalidation risks.
- Evaluate patent family strength and scope concerning global patent rights.
- Consider local law specificities, including exclusions and patent term limitations.
- Maintain thorough prior art searches to safeguard patent validity.
FAQs
1. What are the typical requirements for patentability in Saudi Arabia?
In Saudi Arabia, patents must demonstrate novelty, inventive step, and industrial applicability, aligning with standards set by TRIPS and local law.
2. How long does patent protection last in Saudi Arabia?
Patents are valid for 20 years from the filing date, contingent upon timely payment of maintenance fees.
3. Can a patent claim be amended after filing?
Yes, amendments are permitted during prosecution, subject to restrictions to avoid introducing new matter.
4. How does Saudi Arabia treat pharmaceutical method claims?
Method claims for treatment or diagnosis are generally excluded unless linked to a novel, patentable composition or device.
5. What enforcement options exist for patent holders in Saudi Arabia?
Patent holders can initiate civil litigation for infringement and seek injunctions, damages, and customs enforcement measures.
References
[1] Saudi Patent Law (Royal Decree No. M/38, 2004).
[2] World Intellectual Property Organization (WIPO). Guide to Filing Patents in Saudi Arabia (2022).
[3] European Patent Office (EPO). Patent Landscape Reports (2022).
[4] TRIPS Agreement (1994).
